Secotex Ocas

Tamsulosin Hydrochloride

Method of action: Alpha-Adrenergic Blocking, Alpha-Adrenolytic, Antidisuric, Normalizing The Function Of The Prostate, Urologicals

Treatment option: Benign Prostatic Hyperplasia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Secotex Ocas

Property	Description
Active ingredient	Tamsulosin
Form	Controlled-Release Tablet (OCAS)
Pharmacological class	alpha1-Adrenergic Blocker
Origin	Synthetic/Small-molecule drug

What Type of Medicine is Secotex Ocas?

Secotex Ocas is a specific brand formulation of the medicine containing tamsulosin, which belongs to the class of alpha1-adrenergic blockers. As a prescription-only (Rx) medication developed by the manufacturer Astellas Pharma, it is clinically recognized for its targeted action on the lower urinary tract.

Tamsulosin is a uro-selective type of alpha1-blocker, meaning it primarily targets receptors concentrated in the prostate and bladder neck. Its action relaxes these muscles to improve urinary flow and relieve symptoms of lower urinary tract issues. The substance itself is a small-molecule drug of synthetic origin.

What is the OCAS Tablet Formulation?

OCAS stands for Oral-Controlled Absorption System, a specialized technology that provides a continuous, sustained release of tamsulosin over a 24-hour period. The medication is supplied as a unique controlled-release tablet for oral administration.

This advanced dosage form utilizes a matrix structure to ensure the drug is released at a constant rate, largely independent of food intake. The OCAS formulation provides a steady plasma concentration of tamsulosin over a 24-hour period. This sustained release allows for consistent therapeutic effects throughout the day and supports a once-daily dosing schedule, which is a key distinguishing feature of this particular brand formulation.

What is the General Purpose of Taking Secotex Ocas?

The general purpose of Secotex Ocas is to improve the flow of urine by decreasing the tension in the smooth muscles of the lower urinary tract. A typical use scenario involves helping to ease the difficulty in passing urine and relieving the associated discomfort.

By acting on the alpha1-receptors, the medication relieves the muscle constriction that can otherwise impede the flow of urine. This focused action is what provides the overall benefit of alleviating uncomfortable symptoms associated with tightness or obstruction in the lower urinary tract.

What side effects are possible with Secotex Ocas?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety statements for Secotex Ocas (Tamsulosin Hydrochloride Prolonged-Release Tablets) as documented in official government regulatory sources.

Adverse events are formally grouped by the body system affected and the frequency with which they are reported in clinical data (Very Common, Common, Uncommon, Rare, Very Rare, and Not Known).

System-Organ Class	Common Adverse Reactions (ge 1/100 to < 1/10)
Nervous System Disorders	Dizziness
Reproductive System	Ejaculation disorders (e.g., retrograde ejaculation, anejaculation)
General Disorders	Asthenia, Headache

Serious Adverse Reactions and Key Safety Constraints

Certain reactions are rare but considered clinically significant, requiring immediate attention. These include:

Syncope: Fainting, which is rare.
Angioedema: Serious allergic reactions characterized by swelling of the face, lips, or throat (Very Rare).
Priapism: A persistent, painful, and inappropriate erection that requires urgent medical intervention (Very Rare).
Stevens-Johnson Syndrome: A severe skin reaction (Very Rare).

Secotex Ocas is contraindicated (should not be used) in patients with a known history of orthostatic hypotension and those with hypersensitivity to tamsulosin. The risk of orthostatic hypotension (low blood pressure upon standing) is officially documented and may occur most frequently after the first dose or a dose increase. Additionally, Intraoperative Floppy Iris Syndrome (IFIS), a complication during cataract and glaucoma surgery, has been reported in patients taking or having previously taken tamsulosin. Specific restrictions are noted for patients with severe hepatic impairment.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Secotex Ocas

Overdose scope

Documented overdose presentations: Overdosage with tamsulosin (the active ingredient in Secotex Ocas) may lead to acute hypotension (low blood pressure).

Physiological systems affected (as stated in label): The cardiovascular system is primarily affected, with hypotension being the most noted clinical manifestation of overdose.

Dose-related or exposure-related factors (if applicable): A specific overdose case involving an acute ingestion of 5 mg of tamsulosin hydrochloride reported acute hypotension (systolic blood pressure 70 mm Hg), vomiting, and diarrhea. This dose is significantly higher than the standard therapeutic dose.

Population-specific overdose notes (if applicable): None explicitly stated in official overdose sections.

Emergency-response statements (as written in official documents): Support of the cardiovascular system is of first importance. Blood pressure can be restored and heart rate normalized by keeping the patient in the supine position (lying down). If this measure is insufficient, administration of intravenous fluids and, if necessary, vasopressors should be considered.

When immediate medical help is required (label-derived phrasing only): Immediate medical attention is required for any suspected overdose to address acute hypotension and cardiovascular system support.

Overdose classifications (high-level)

Severity classification (as defined in official documents): Overdose is classified primarily by the potential for acute, symptomatic hypotension.

Regulatory basis (EMA / FDA / etc.): Information is derived from official labeling/product monographs for tamsulosin hydrochloride.

Overdose-context constraints (as defined in official documents): Dialysis is unlikely to be of benefit due to the high protein binding of tamsulosin. Measures to impede absorption, such as gastric lavage or administering activated charcoal and an osmotic laxative, can be taken.

Resulting overdose structure

Official overdose statements:

The most likely clinical manifestation of overdose is acute hypotension.
Support of the cardiovascular system is the first priority.
If hypotension occurs, the patient should be placed in the supine position and treated with volume expanders or vasopressors as needed.

Connection to the overall overdose profile (2–4 sentences): The official regulatory documents define the Secotex Ocas overdose profile as one primarily presenting with cardiovascular effects, specifically acute hypotension, consistent with its mechanism as an alpha-blocker. Emergency seeking conditions are centered on the need for urgent cardiovascular support, including restoring blood pressure and normalizing heart rate. The official guidance emphasizes general supportive measures, fluid management, and the use of vasopressors if blood pressure remains low, while noting that dialysis is ineffective.

Therapeutic Uses of Secotex Ocas

What Secotex Ocas Treats: Main Uses and Benefits

Secotex Ocas is applied across therapeutic domains centered on relieving symptomatic discomfort associated with the lower urinary tract, particularly in adult men. It is considered relevant in contexts where symptoms may interfere with daily functioning, providing supportive relief.

Tamsulosin is commonly used to address symptoms related to Benign Prostatic Hyperplasia (BPH) and the array of associated urinary difficulties.

The medication is generally applied in addressing symptoms related to physical discomfort such as a weak or slow urine stream, straining (hesitancy), and the disruptive storage symptoms of the bladder, including urgency and nocturia. This therapeutic support is also applied in clinical settings that involve acute or unstable symptom patterns, such as assisting with the passage of ureteral stones or helping to maintain functional stability following catheter removal. The medication contributes to easing the overall symptom load.

“This offers symptomatic relief that helps patients cope more steadily and supports general well-being during symptomatic phases.”

Quick Fact: Is used for managing Voiding Dysfunction The medication assists in easing symptoms of obstruction, providing supportive relief that may assist with the process of urine passage, and is relevant when symptoms become difficult to tolerate.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Secotex Ocas

Secotex Ocas (tamsulosin hydrochloride) is primarily intended for use in adult male patients and is not indicated for women or the pediatric population.

Contraindications: The medicine must NOT be used by patients with:

A known history of hypersensitivity or allergy to tamsulosin or any other component of the product.
A history of orthostatic hypotension (a drop in blood pressure when changing position).
Severe hepatic insufficiency (severe liver problems).
Concomitant use with strong inhibitors of the enzyme CYP3A4 (such as certain antifungal agents).
Concomitant use with other alpha-adrenergic blocking agents.

Use Requires Special Caution or is Not Recommended:

Population/Condition	Regulatory Status
Scheduled for cataract/glaucoma surgery	Not recommended (due to risk of IFIS)
Severe renal impairment (CLcr < 10 mL/min)	Use with caution (not sufficiently studied)
Pediatric population (<18 years)	Not indicated (safety and efficacy not established)

This information is based on official government regulatory documents (e.g., FDA, EMA) and strictly defines the approved and non-approved populations for this medication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Tamsulosin (Secotex Ocas) based on metabolic clearance and additive pharmacodynamic effects.

Formally Contraindicated Combinations

Classification	Examples of Interacting Medicines	Rationale (Official Labeling)
Contraindicated	Strong CYP3A4 Inhibitors (e.g., Ketoconazole)	Significant increase in Tamsulosin systemic exposure (AUC and C max) is expected.
Contraindicated	Other Alpha-Adrenergic Blocking Agents (e.g., Doxazosin, Prazosin)	Increased risk of severe symptomatic hypotension due to additive alpha1-blockade.

Mechanism of Action

Secotex Ocas (Tamsulosin) functions as a selective and competitive alpha1-adrenoceptor antagonist. The compound preferentially targets the alpha1A and alpha1D adrenergic receptor subtypes. These receptors are densely localized on the smooth muscle cells of the prostatic capsule, prostate gland, prostatic urethra, and bladder neck. Antagonism of these receptors blocks the binding of endogenous catecholamines, thereby inhibiting sympathetic nervous system-mediated signal transduction. This mechanistic action results in the relaxation of smooth muscle tone throughout the lower urinary tract structure. The molecular cascade ultimately reduces the basal contractile tension within the prostate and bladder neck, causing system-level physiological modulation that decreases urethral resistance. This pharmacodynamic effect is mediated solely at the receptor and tissue level, affecting organ contractility without invoking systemic vascular changes or clinical outcomes.

Dosage and Administration Information

How to Use Secotex Ocas (Tamsulosin Prolonged-Release)

This section outlines the administration instructions for Secotex Ocas (tamsulosin 0.4 mg prolonged-release tablets).

Official Administration Guidelines

Usage Entity	Regulatory Instruction
Route of Administration	Oral use only.
Standard Dosing Schedule	One 0.4 mg prolonged-release tablet once daily.
Timing Relative to Meals	Can be taken independently of food (specific to the prolonged-release tablet formulation).
Missed Dose	If treatment is interrupted for several days, it should be restarted at the standard dose of 0.4 mg once daily.

Procedural Instructions and Constraints

The prolonged-release formulation requires adherence to specific methods to ensure proper release of the active substance over 24 hours:

The tablet must be swallowed whole.
The tablet must not be crunched, chewed, or crushed.

Population-Specific Rules

Paediatric Population: The drug is not indicated for use in individuals under 18 years of age.
Renal Impairment: No dose adjustment is typically warranted for patients with renal impairment.
Severe Hepatic Impairment: The drug is contraindicated in patients with severe hepatic insufficiency.

Summary of Protocol

The protocol involves the administration of a single, whole tablet once every 24 hours, regardless of food intake. Adherence to the swallowing-whole constraint is a central aspect of use, as it ensures the integrity of the extended-release system.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Secotex Ocas

The information presented here summarizes the structure and focus of the clinical research for tamsulosin (the active ingredient in Secotex Ocas) as reported in authoritative scientific literature and regulatory documents. This overview describes what the studies explored, the general patterns observed, and where the current evidence remains uncertain.

Evidence for Symptomatic Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms (LUTS)

Research involving tamsulosin for conditions characterized by fluctuating symptoms of BPH and LUTS has primarily involved Randomized Controlled Trials (RCTs). These trials were used in research exploring how symptoms change over time and included adult men experiencing moderate-to-severe lower urinary tract symptoms. The studies focused on standardized measurements of patient-reported outcomes describing perceived discomfort and functional outcomes, such as the maximum rate of urine flow (Qmax).

In these trials, researchers examined changes in the International Prostate Symptom Score (IPSS), a scale that is relevant in evidence describing how symptoms are measured. Studies report how symptoms evolved in the observed populations, noting changes over observation periods typically lasting 8 to 12 weeks. The evidence level for this indication is often graded as High, based on the numerous, well-designed RCTs and meta-analyses. However, research exploring long-term symptom management beyond a few years is often conducted in open-label extension studies or combination therapy protocols.

Evidence for Ureteral Stone Passage (Medical Expulsive Therapy)

Research explored the use of tamsulosin in individuals with ureteral stones, a situation associated with acute or disruptive episodes. This research primarily consisted of Randomized Controlled Trials (RCTs) designed to examine temporary physiological imbalance. The trials measured and reported outcomes describing episodic or acute changes, focusing mainly on the stone-free rate and the time required for expulsion.

Research so far indicates that the findings were mixed when analyzing all sizes of ureteral stones together, with evidence quality often described as Moderate. Studies suggest that the measured changes in stone passage rates are less consistent for very small ureteral stones, which often pass spontaneously. Furthermore, the follow-up durations were limited, meaning the research provides limited insight into long-term or recurrent stone disease management.

What the Research Landscape Shows is Still Uncertain

While extensive evidence contributes to the broader evidence landscape for tamsulosin, certain areas remain where the certainty remains low or where more research is ongoing.

Evidence for very long-term outcomes is limited; specifically, the long-term effects related to BPH progression over many years data are still emerging from dedicated, controlled trials.
Findings were mixed regarding the consistent measured change in stone passage rates across all sizes of ureteral stones, particularly smaller stones.
Comparative evidence is lacking for some of the long-term clinical outcomes that are important in conditions marked by functional limitations.

The research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.

Key Studies & References

Tamsulosin NIH MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Secotex Ocas (FAQ)

Q: How quickly should a person expect Secotex Ocas to start having an effect?

Secotex Ocas is formulated to release the active substance in a continuous, sustained manner. Official product information indicates that the concentration of the drug reaches its highest level in the blood typically within about six to seven hours after a dose. While this shows when the medicine is most available in the body, the therapeutic effect on symptoms may take a few days or weeks to be fully noticed.

Q: Is Secotex Ocas typically a medicine that is taken for a long period of time?

Yes, for the treatment of symptoms related to an enlarged prostate, this medicine is often intended for long-term use. Regulatory guidance states that if the medicine is deemed appropriate for symptom management, it can be continued over an extended period.

Q: Are there known effects from stopping Secotex Ocas after taking it regularly?

Studies on discontinuing the medicine indicate that stopping treatment can cause a return or worsening of the original urinary symptoms. If treatment needs to be stopped, this change can impact the overall effectiveness of the therapeutic outcome.

Q: Can Secotex Ocas affect a person's ability to drive or use machinery?

Official warnings note that this medicine can cause side effects such as dizziness, vertigo, and, rarely, fainting (syncope). Because of these potential effects, official information describes a requirement for caution when performing tasks that require concentration, such as driving or operating heavy machinery.

Q: Is Secotex Ocas available as a generic medicine under a different name?

The active ingredient in Secotex Ocas is tamsulosin. While tamsulosin is widely available in generic forms approved by regulatory agencies, the specific OCAS (Oral-Controlled Absorption System) technology that provides a sustained release is unique to this brand formulation.

Q: Is there information regarding the use of Secotex Ocas in people with a history of heart issues?

Official safety constraints specifically mention the risk of low blood pressure upon standing (orthostatic hypotension) and fainting (syncope), which are cardiovascular effects. Official regulatory documents list a known history of orthostatic hypotension as a contraindication.

Q: Do older adults typically experience different side effects compared to younger patients using Secotex Ocas?

Clinical studies have generally not shown that older adults (those aged 65 and above) experience adverse reactions more frequently than younger individuals. However, official information does note that the body's processing of the drug may be slightly prolonged in older individuals.

Q: How is this drug different from other alpha-blockers I may have heard of?

Secotex Ocas contains tamsulosin, which is defined by regulatory documents as a uro-selective alpha-blocker. This means that the medicine primarily targets the receptors concentrated in the smooth muscles of the lower urinary tract, such as the prostate and bladder neck.

Q: Can Secotex Ocas affect sleep patterns?

Yes, this medicine may affect sleep patterns. Regulatory documentation lists both insomnia (difficulty sleeping) and somnolence (drowsiness) as adverse reactions reported in clinical data.

Q: Why is Secotex Ocas available in different dose strengths?

Official prescribing information indicates that while one strength is the standard starting dose, another strength exists for use when the initial strength is deemed inadequate after a few weeks of treatment. The availability of different strengths supports clinical prescribing protocols.

Q: Have users reported experiencing mental fogginess or trouble concentrating while taking this medicine?

Reports from clinical data include central nervous system effects such as dizziness and somnolence (drowsiness). Post-marketing reports have also included instances of confusion, which can relate to mental fogginess or trouble concentrating.

Q: How does the body process and remove Secotex Ocas after it is absorbed?

After the medicine is absorbed, it is extensively broken down through metabolic processes, mainly by specific enzymes in the liver. The processed substance is then primarily removed from the body through the kidneys in the urine.

Q: What happens to the overall treatment effectiveness if a person misses multiple doses of Secotex Ocas?

Clinical data on discontinuing the medicine indicate that stopping treatment can lead to a return or worsening of urinary symptoms. If treatment is interrupted for multiple days, official product information provides a protocol for restarting the medicine at the standard strength following a period of interruption.

Q: Does Secotex Ocas interfere with the results of any standard medical or blood tests?

According to official product information, there are no known clinically significant interactions between this medicine and standard laboratory or blood tests. Specifically, studies have shown that it does not significantly affect Prostate-Specific Antigen (PSA) levels.

How should Secotex Ocas be stored and disposed of?

Storage and Disposal of Secotex Ocas

Secotex Ocas (Tamsulosin Ocas) must be stored and disposed of according to strict regulatory guidelines to ensure product stability and environmental safety.

Storage Requirements

Storage Condition Type	Requirement
Temperature/Light	Does not require any special storage conditions concerning temperature, but must be protected from environmental factors.
Container Rule	Must be stored in the original pack (blister pack) until the tablets are used.
Stability	Do not use the tablets after the expiry date printed on the packaging.
Child Safety	Keep out of the reach and sight of children at all times.

️ Disposal Instructions

Unused or expired Secotex Ocas must be disposed of properly to protect the environment. Do not dispose of this medicine via wastewater or household waste. For correct disposal, the product should be returned to a pharmacist or a pharmaceutical waste collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.